GlaxoSmithKline CR`s EBITDA Growth reached 56.0 % in 2017. This is 202 % less than in the previous year.
Buy EBITDA Growth data for GlaxoSmithKline Czech Republic.
$19.99Buy all data for GlaxoSmithKline Czech Republic.
Buy annual subscriptions for all our products.
| Company | Unit | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| Amgen Czech Republic | % | ... | ... | ... | ... | ... | 50.4 | -36.1 | 10.4 | 32.3 | -15.0 | |||||||
| Bayer Czech Republic | % | ... | ... | ... | -0.531 | -33.0 | 20.7 | 5.62 | 17.5 | |||||||||
| GlaxoSmithKline Czech Republic | % | ... | ... | ... | 27.4 | -24.7 | -19.4 | -26.0 | -0.486 | |||||||||
| Merck Czech Republic | % | ... | ... | 170 | 24.9 | -41.2 | 8.97 | 78.8 | ||||||||||
| Novartis Czech Republic | % | 3.11 | 13.4 | 2.54 | 57.5 | 15.7 | ||||||||||||
| Pfizer Czech Republic | % | ... | ... | 93.1 | -79.0 | 160 | -0.368 | -35.9 | ||||||||||
| Roche Czech Republic | % | ... | ... | ... | -18.2 | -1.49 | 60.6 | -19.3 | -21.0 | ... | ||||||||
| Sanofi-Aventis Czech Republic | % | ... | ... | ... | ... | 26.7 | -10.9 | 22.2 | -82.8 | 455 | ||||||||
| Servier Czech Republic | % | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | 4.70 | 3.39 | 14.6 | ||
| Walmark | % | ... | ... | ... | 14.2 | -56.9 | -15.1 | 70.2 | -212 |
Helgi Library 
